PAZINIB 400 MG

About

PAZINIB 400 MG is a potent oral tyrosine kinase inhibitor primarily used in oncology. It targets multiple receptor tyrosine kinases, including vascular endothelial growth factor receptors (VEGFR-1, -2, and -3), platelet-derived growth factor receptors (PDGFR-α and -β), and c-KIT. By inhibiting these pathways, PAZINIB interferes with tumor angiogenesis, cell proliferation, and survival, thereby impeding tumor growth and metastasis. It is indicated for the treatment of advanced renal cell carcinoma and advanced soft tissue sarcoma in patients who have received prior chemotherapy. Its mechanism of action involves blocking the signals that promote blood vessel formation within tumors and the growth of cancer cells themselves, leading to a reduction in tumor size and progression.

This medication requires careful patient selection and monitoring due to its specific mechanism and potential for significant adverse effects. It represents a targeted therapy approach, offering a valuable option for patients with specific types of advanced cancers where traditional treatments may have limited efficacy. Regular assessment of patient response and management of side effects are crucial for optimizing treatment outcomes.

Uses

• Advanced renal cell carcinoma
• Advanced soft tissue sarcoma
• Ovarian cancer (off-label)
• Non-small cell lung cancer (off-label)

Directions For Use

Take orally once daily, typically without food (at least one hour before or two hours after a meal). Follow your physician's instructions precisely.

Benefits

• Prolongs progression-free survival in specific cancers
• Reduces tumor size and inhibits metastasis
• Improves overall survival in certain patient populations
• Offers a targeted therapy approach
• Oral administration for patient convenience
• Effective in advanced stages of disease

Side Effects

• Hypertension
• Fatigue
• Nausea
• Diarrhea
• Hair color changes
• Elevated liver enzymes
• Proteinuria
• Headache
• Vomiting
• Anorexia
• Hand-foot syndrome
• Rash

Safety Measures

• Alcohol - Avoid or limit alcohol consumption due to the potential for increased liver toxicity and exacerbation of side effects.
• Pregnancy - Contraindicated during pregnancy as it can cause fetal harm. Women of childbearing potential must use effective contraception during treatment and for at least 2 weeks after the last dose.
• Breastfeeding - Not recommended during breastfeeding. It is unknown if PAZINIB is excreted in human milk, but potential for serious adverse reactions in the infant exists.
• Liver - Use with caution in patients with hepatic impairment. Dose adjustment may be necessary, and liver function should be monitored closely before and during treatment.
• Kidney - Use with caution in patients with renal impairment. No specific dose adjustment is typically needed for mild to moderate impairment, but data for severe impairment is limited.
• Lung - Monitor for signs and symptoms of interstitial lung disease/pneumonitis. Discontinue treatment if suspected or confirmed.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.